At its meeting on 13-14 February 2014, the Committee reviewed an application from Roche for the funding of pertuzumab (Perjeta) for the first-line treatment of patients with HER-2 positive metastatic breast cancer in combination with trastuzumab and docetaxel.

The Committee recommended that pertuzumab should be funded, when used in combination with trastuzumab for the first-line treatment of patients with HER-2 positive metastatic breast cancer. Members gave this recommendation a low priority.

For more details, go to: http://www.pharmac.health.nz/assets/ptac-minutes-2014-02.pdf